• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Clovis Divests Remaining Assets, Including Rubraca Cancer Drug, for Over $70 Million


Bankrupt Clovis Oncology offloads assets, including ovarian cancer drug Rubraca, to Swiss firm Pharma& Schweiz for over $70 million.

Four months after filing for bankruptcy, Clovis Oncology has agreed to sell its remaining assets, including the rights to ovarian cancer drug Rubraca, to Swiss company Pharma& Schweiz GmbH for $70 million upfront, with an additional $50 million tied to regulatory milestones and $15 million in sales-related milestones. Commercial challenges with Rubraca, approved in 2016, contributed to the company's failure. Rubraca is a PARP inhibitor, a class of cancer drugs currently under scrutiny, including AstraZeneca and Merck's Lynparza and GSK's Zejula.

Reference: Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus. April 7, 2023 / FiercePharma

Related Videos